N/A
N=445
Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Covid19 and Mortality
Bottom Line
View on ClinicalTrials.gov: NCT04659876 ↗Enrolled (actual)
445
Serious AEs
—
Results posted
Jan 2026
Primary outcome: Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- clinical features and laboratory values (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
- Primary completion
- Sep 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acute Physiology and Chronic Health Evaluation II Score |
13.1; 18.3 | — |
| PRIMARY Sequential Organ Failure Assessment Score |
3.3; 4.8 | — |
| PRIMARY Kidney Disease: Improving Global Outcomes Scores |
113; 76; 17; 66; 12; 67 | — |
| PRIMARY White Blood Cell |
10.6; 11.6 | — |
| PRIMARY Neutrophil |
8.75; 9.9 | — |
| PRIMARY Lymphocyte |
1.1; 0.93 | — |
| PRIMARY Neutrophil Lymphocyte Ratio |
9.4; 14.5 | — |
| PRIMARY Comorbidities |
42; 65; 107; 231 | — |
| PRIMARY Diabetes |
38; 89 | — |
| PRIMARY Hypertension |
64; 114 | — |
| PRIMARY Chronic Obstructive Pulmonary Disease |
19; 26 | — |
| PRIMARY Chronic Kidney Disease |
12; 22 | — |
| PRIMARY Cardiovascular Disease |
19; 47 | — |
| PRIMARY Hemoglobin |
13.06; 12.6 | — |
| PRIMARY Hematocrit |
40.61; 41.2 | — |
| PRIMARY Platelet |
253.4; 237.3 | — |
| PRIMARY Prothrombin Time |
13.3; 14.1 | — |
| PRIMARY D-dimer |
954.5; 2564.4 | — |
| PRIMARY Blood Gas Analysis-pH |
7.38; 7.36 | — |
| PRIMARY Partial Oxygen Pressure |
42.14; 40.3 | — |
| PRIMARY Partial Pressure of Carbon Dioxide |
39.1; 38.61 | — |
| PRIMARY Bicarbonate |
23.02; 21.16 | — |
| PRIMARY Lactate |
2.2; 3.04 | — |
| PRIMARY Lactate Dehydrogenase |
406.7; 569.4 | — |
| PRIMARY Creatine Kinase |
204.4; 369.4 | — |
| PRIMARY C-reactive Protein |
120.4; 151.7 | — |
| PRIMARY Blood Urea Nitrogen |
47.6; 72.5 | — |
| PRIMARY Creatinine |
1.28; 1.68 | — |
| PRIMARY Alanine Aminotransferase |
32.2; 47.9 | — |
| PRIMARY Aspartate Aminotransferase |
40.8; 81.5 | — |
| PRIMARY Total Bilirubin |
0.68; 0.75 | — |
| PRIMARY Direct Bilirubin |
0.34; 0.4 | — |
| PRIMARY Indirect Bilirubin |
0.33; 0.33 | — |
| PRIMARY Procalcitonin |
1.39; 4.13 | — |
| PRIMARY Ferritin |
673.8; 951.5 | — |
| SECONDARY Length of Stay in the Intensive Care Unit |
13.02; 10.3 | — |
Summary
Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak. The first cases in this region were seen on March 22, 2020. In this study, it is aimed to retrospectively examine critical patients admitted to the intensive care unit (ICU) due to COVID-19 from the first onset of cases until September 01, 2020 and to examine the factors affecting mortality. The necessary permits for the study were obtained from the Scientific Research Platform of the T.R. Ministry of Health and the Ethics Committee of the Gazi Yasargil educational and Research Hospital in Diyarbakır. (No: 550, 11.09.2020) Patients diagnosed with COVID-19 on the specified dates, followed in the ICU, older than 18 years, identified as critical/serious according to the World Health Organization and provisional guidelines of the Scientific Board of the T.R. Ministry of Health will be included in the study.
ICU patients without COVID-19; COVID-19 patients under 18 years of age; COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography will be excluded from the study.
Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Kidney Disease: Improving Global Outcomes (KDIGO) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, Partial oxygen pressure-PO2, Partial pressure of carbon dioxide-PCO2, bicarbonate-HCO3, lactate), coagulation parameters (prothrombin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , urea, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
Patients will be divided into two groups according to their clinical results as those without mortality during ICU follow-up (Group S) and those with mortality (Group NS). The clinical characteristics of both groups, APACHE II, SOFA, KDIGO scores and laboratory results at the first admission to the ICU will be compared. With the diagnosis of COVID-19, factors affecting mortality in critical patients in the ICU will be tried to be determined.
Eligibility Criteria
Inclusion Criteria
- During the period between 22.03.2020 and 01.09.2020, critical patients over the age of 18 who were admitted to the ICU of Diyarbakır Gazi Yasargil Educational and Research Hospital due to COVID-19 will be included in the study.
Exclusion Criteria
- ICU patients without COVID-19
- COVID-19 patients under 18 years of age
- COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography
Data sourced from ClinicalTrials.gov (NCT04659876). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.